Search Results

There are 20197 results for: content related to: Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

  1. You have free access to this content
    The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 10, November 2015, Pages: 1192–1199, G. Dumitrescu, A. Amiot, P. Seksik, C. Baudry, C. Stefanescu, C. Gagniere, M. Allez, J. Cosnes and Y. Bouhnik

    Version of Record online : 10 SEP 2015, DOI: 10.1111/apt.13393

  2. Infliximab dose intensification in Crohn's disease

    Inflammatory Bowel Diseases

    Volume 13, Issue 9, September 2007, Pages: 1093–1099, Miguel Regueiro, Benjamin Siemanowski, Kevin E. Kip and Scott Plevy

    Version of Record online : 4 MAY 2007, DOI: 10.1002/ibd.20177

  3. You have free access to this content
    The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 3, February 2011, Pages: 349–357, U. Kopylov, G. J. Mantzaris, K. H. Katsanos, C. Reenaers, P. Ellul, J. F. Rahier, E. Israeli, P. L. Lakatos, G. Fiorino, M. Cesarini, E. V. Tsianos, E. Louis and S. Ben-Horin

    Version of Record online : 1 DEC 2010, DOI: 10.1111/j.1365-2036.2010.04523.x

  4. Infliximab for the treatment of rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Barbara BTB Blumenauer, Maria Judd, George A Wells, Amanda Burls, Ann Cranney, Marc C Hochberg, Peter Tugwell and Maria Angeles Lopez-Olivo

    Published Online : 22 JUL 2002, DOI: 10.1002/14651858.CD003785

  5. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  6. Review article: dose optimisation of infliximab for acute severe ulcerative colitis

    Alimentary Pharmacology & Therapeutics

    Volume 45, Issue 5, March 2017, Pages: 617–630, P. Hindryckx, G. Novak, N. Vande Casteele, D. Laukens, C. Parker, L. M Shackelton, N. Narula, R. Khanna, P. Dulai, B. G Levesque, W. J Sandborn, G. D'Haens, B. G. Feagan and V. Jairath

    Version of Record online : 11 JAN 2017, DOI: 10.1111/apt.13913

  7. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  8. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 7, July 2012, Pages: 1199–1206, Benjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, Marine Desroches, Gauthier Louis, Chiara De Cassan, Clotilde Baudry, Jean-Marc Gornet, Pierre Desreumaux, Dominique Emilie, Jean-Frédéric Colombel and Matthieu Allez

    Version of Record online : 29 AUG 2011, DOI: 10.1002/ibd.21839

  9. You have free access to this content
    Practical application of anti-TNF therapy for luminal Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 11, November 2011, Pages: 2366–2391, Michael A. Kamm, Siew C. Ng, Peter De Cruz, Patrick Allen and Stephen B. Hanauer

    Version of Record online : 18 FEB 2011, DOI: 10.1002/ibd.21655

  10. You have free access to this content
    Arthritis & Rheumatism, 2001 Annual Scientific Meeting Abstracts, November 10–15, 2001, San Francisco, CA

    Arthritis & Rheumatism

    Volume 44, Issue S9, September 2001, Pages: 53–165,

    Version of Record online : 22 FEB 2002, DOI: 10.1002/1529-0131(200109)44:9+<::AID-ART425>3.0.CO;2-A

  11. You have free access to this content
    Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 118–128, David Ternant, Emilie Ducourau, Aleth Perdriger, Anca Corondan, Benoît Le Goff, Valérie Devauchelle-Pensec, Elisabeth Solau-Gervais, Hervé Watier, Philippe Goupille, Gilles Paintaud and Denis Mulleman

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12313

  12. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

    Alimentary Pharmacology & Therapeutics

    Volume 44, Issue 7, October 2016, Pages: 673–683, T. Billiet, I. Cleynen, V. Ballet, M. Ferrante, G. Van Assche, A. Gils and S. Vermeire

    Version of Record online : 9 AUG 2016, DOI: 10.1111/apt.13754

  13. You have free access to this content
    Tumor Necrosis Factor Alpha Inhibitors as Immunomodulatory Antirejection Agents after Intestinal Transplantation

    American Journal of Transplantation

    Volume 11, Issue 5, May 2011, Pages: 1041–1050, U. A. Gerlach, M. Koch, H.-P. Müller, W. Veltzke-Schlieker, P. Neuhaus and A. Pascher

    Version of Record online : 26 APR 2011, DOI: 10.1111/j.1600-6143.2011.03497.x

  14. INFECTION-RELATED RHEUMATIC DISEASES

    APLAR Journal of Rheumatology

    Volume 9, Issue s1, August 2006, Pages: A80–A83,

    Version of Record online : 6 JUL 2006, DOI: 10.1111/j.1479-8077.2006.00199_14.x

  15. Durability of infliximab in Crohn's disease: A single-center experience

    Inflammatory Bowel Diseases

    Volume 15, Issue 12, December 2009, Pages: 1837–1843, Jason E. Gonzaga, Ashwin N. Ananthakrishnan, Mazen Issa, Dawn B. Beaulieu, Sue Skaros, Yelena Zadvornova, Kathryn Johnson, Mary F. Otterson and David G. Binion

    Version of Record online : 21 MAY 2009, DOI: 10.1002/ibd.20974

  16. You have free access to this content
    The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

    Arthritis & Rheumatism

    Volume 46, Issue 6, June 2002, Pages: 1451–1459, E. William St.Clair, Carrie L. Wagner, Adedigbo A. Fasanmade, Benjamin Wang, Thomas Schaible, Arthur Kavanaugh and Edward C. Keystone

    Version of Record online : 6 JUN 2002, DOI: 10.1002/art.10302

  17. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

    Inflammatory Bowel Diseases

    Volume 13, Issue 1, January 2007, Pages: 2–11, Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton and Stephen B. Hanauer

    Version of Record online : 19 DEC 2006, DOI: 10.1002/ibd.20014

  18. CELL RECEPTOR-LIGAND INTERACTION, SIGNALING AND ACTIVATION

    APLAR Journal of Rheumatology

    Volume 9, Issue s1, August 2006, Page: A39,

    Version of Record online : 6 JUL 2006, DOI: 10.1111/j.1479-8077.2006.00199_6.x

  19. You have free access to this content
    When to use biological agents in inflammatory bowel disease

    Journal of Gastroenterology and Hepatology

    Volume 27, Issue 7, July 2012, Pages: 1141–1149, Crispin Corte, Payal Saxena, Stephen Tattersall, Christian Selinger and Rupert W Leong

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1440-1746.2011.07056.x

  20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Brian W Behm and Stephen J Bickston

    Published Online : 23 JAN 2008, DOI: 10.1002/14651858.CD006893